Megalabs has acquired majority interest and control of DS Laboratories (“DS Labs”), a leading dermatology company focused on science backed hair care across 50+ countries.  This strategic move enhances Megalabs’ position in the global dermatology market and the US.

For Megalabs, dermatology is a key focus area with a long and successful track record driven by its Medihealth line, including a wide portfolio of products, and more recently entering the minimally invasive aesthetics and fillers market with the acquisition of Croma-Pharma in Brazil and the distribution of its products in the Latam region.

DS Labs’ portfolio is highly relevant for the operation as it will strengthen Megalabs’ position in dermatology and the US market.

Fabian Rivero, MBA, Megalabs North America’s CEO, emphasized that this acquisition boosts the company’s growth and presence in the US with high-quality products, as “DS Labs is known for its science backed hair care and skin care products”.

DS Labs will benefit from Megalabs’ distribution network and operational expertise, accelerating the development and delivery of new treatments globally.

“Our mission has always been to improve patient outcomes through dermatological science,” said Fernando Tamez, Director of DS Labs. “Joining Megalabs allows us to expand our reach and impact”.

Megalabs and DS Labs are united in their pursuit of innovation and growth. The collaboration will involve a strong emphasis on constructive teamwork and professionalism to ensure DS Labs’ portfolio of effective dermatological treatment options is accessible to patients worldwide.

DS Labs was advised by M&A advisor Raymond James, legal advisors Cowan, DeBaets, Abrahams & Sheppard LLP and Recalde Law Firm, P.A. and accounting & tax due diligence advisor Alvarez & Marsal. Megalabs was advised by Megalabs M&A team and legal advisors Greenberg Traurig.

For further information please read press release

Download Document

DS Labs